InvestorsHub Logo

Mark954

08/27/23 1:10 PM

#5043 RE: Potse #5038

I'm pretty sure that they'll be utilizing the TCRI shell in some capacity. I'm thinking it may end up being tied into this UAE IPO somehow. Why else would they be holding onto it and paying all the bills? I've always believed that they (Phoenix/Munaf/Bijan/other insiders) would want to see a ROI at some point, and what better way than taking things public. Good to have a little insight on what they're thinking at the moment. I also have that M2 thing lingering in the back of my mind as well.

Mark out

Mark954

08/28/23 7:22 AM

#5047 RE: Potse #5038

Consider this regarding TCRI:

Foreign companies often choose to list on foreign exchanges but trade Over-the-Counter (OTC) in the United States for a variety of reasons, including regulatory, cost, and visibility considerations:

* Regulatory Differences: Listing on a foreign exchange may involve complying with different regulatory requirements and standards. The regulatory landscape in the U.S. can be complex and demanding, which might deter some foreign companies from directly listing on U.S. exchanges. By trading OTC, they can avoid some of the regulatory hurdles associated with a formal U.S. exchange listing.

* Cost Considerations: Listing on major U.S. exchanges like the New York Stock Exchange (NYSE) or NASDAQ can be expensive due to listing fees, compliance costs, legal fees, and ongoing reporting requirements. Trading OTC might offer a more cost-effective way for foreign companies to access U.S. investors without incurring the high costs of a formal exchange listing.

* Market Access: By trading OTC, foreign companies can still gain access to U.S. investors without necessarily having to comply with all the listing requirements of a U.S. exchange. This is particularly attractive for smaller foreign companies that may not meet the stringent criteria for a U.S. exchange listing.

* Liquidity and Visibility: While trading OTC may offer access to U.S. investors, it might not provide the same level of liquidity and visibility as a major U.S. exchange. However, for some foreign companies, the OTC market can still provide a platform to engage with U.S. investors and build brand recognition over time.

* Flexibility: OTC trading can be more flexible in terms of reporting requirements and ongoing obligations. Foreign companies might prefer this flexibility, especially if their reporting and governance practices differ from U.S. standards.

* Timing and Strategy: Some foreign companies might use the OTC market as an initial step to gauge U.S. investor interest before committing to a full exchange listing. It allows them to test the waters and assess market demand without making a significant upfront commitment.

* Dual-Listing Strategy: In some cases, foreign companies might pursue a dual-listing strategy, where they maintain their primary listing on their home exchange and also trade OTC in the U.S. This strategy can offer a compromise between regulatory requirements and market access.

* Risk Perception: Some foreign companies might perceive trading OTC as less risky in terms of compliance and regulatory obligations compared to listing on a major U.S. exchange, which can be seen as a more stringent and closely scrutinized environment.

It's important to note that each company's decision is influenced by its specific circumstances, goals, and market conditions. The choice between listing on a foreign exchange and trading OTC in the U.S. involves a careful consideration of factors such as regulatory complexity, costs, market visibility, and investor preferences.

Mark954

09/30/23 11:20 AM

#5123 RE: Potse #5038

Very interesting stuff happening in the U.A.E. https://www.foxbusiness.com/video/6338085750112
The U.S. better get their head out of their ass or they'll be left behind...........Quick! One hard headed guy holding things back. The U.S. should be leading the way and we're not.

Mark out